Brolucizumab for the treatment of proliferative diabetic retinopathy (PDR): 54-week results from the CONDOR study

Abstract

Purpose : To evaluate the 54-week efficacy and safety of brolucizumab vs. panretinal photocoagulation in PDR.

Methods : The CONDOR trial was a 96-week two-arm, randomized, single-masked, active controlled phase 3 study in subjects with PDR receiving brolucizumab 6 mg and panretinal photocoagulation (PRP). Patient randomization was 1:1 to brolucizumab 6mg or PRP. The Brolucizumab arm received 3 loading doses every 6 weeks (q6w) followed by q12w dosing, allowing more frequent injections at predefined disease activity assessment visits. Initial treatment of PRP in 1-4 sessions up to Week 12, followed with additional PRP treatment as needed.

Results : The primary objective was to demonstrate that brolucizumab is non-inferior to PRP with respect to the change from Baseline in visual acuity at Week 54. The secondary objective was to demonstrate that brolucizumab is superior to PRP in reducing diabetic retinopathy progression, center-involving diabetic macular edema, vision threatening ocular complications and to assess the safety and tolerability of brolucizumab relative to PRP.

Conclusions : The 1-year result from the CONDOR study affirms the efficacy of brolucizumab 6mg in the treatment of PDR and the expected safety profile.

This abstract was presented at the 2024 ARVO Annual Meeting, held in Seattle, WA, May 5-9, 2024.